COMBINED TEST
Why get tested?
The test, together with the measurement of the nuchal translucency (NT) and the clinical-anamnestic data of the pregnant woman, allows to evaluate the risk of a fetus presenting chromosomal abnormalities.
The test is suitable for all pregnant women and, in particular, for women over the age of 35 who have an increased risk of having a fetus affected by trisomy 21, 13 or 18.
What the test detects
The test quantifies PAPP-A and free-beta-hCG proteins.
What variants cause
The test identifies an increased risk of a fetus having chromosomal abnormalities.
How testing works
The test is performed on a maternal venous blood sample for the quantification of PAPP-A and free-beta-hCG proteins.
Reporting time
Results in 2-3 working days.
Sensitivity and specificity
Diagnostic sensibility for trisomy 21 is 90%.